Newcelx Ltd. - (NCEL) closed at $2.69 on November 19, 2026, up 1.5% from the previous close, on volume of 4,697 shares (30-day average 20,771).
Data as of November 19, 2026.
NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
Globe Newswire (Mon, 9-Nov 9:00 AM ET)
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Globe Newswire (Mon, 28-Sep 8:00 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Newcelx Ltd. - trades on the NASDAQ stock market under the symbol NCEL.
As of November 19, 2026, NCEL stock price climbed to $2.69 with 4,697 million shares trading.
NCEL has a beta of 1.82, meaning it tends to be more sensitive to market movements. NCEL has a correlation of 0.06 to the broad based SPY ETF.
NCEL has a market cap of $15.54 million. This is considered a Sub-Micro Cap stock.
NCEL has underperformed the market in the last year with a return of -20.9%, while the SPY ETF gained +9.6%. In the last 3 month period, NCEL fell short of the market, returning -20.6%, while SPY returned -6.5%. However, in the most recent 2 weeks NCEL has outperformed the stock market by returning +5.1%, while SPY returned -6.6%.
NCEL support price is $2.40 and resistance is $2.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCEL shares will trade within this expected range on the day.